hepatocellular carcinoma Clinical Trials and Research
Also known as: liver cancer, primary liver cancer, hcc, malignant hepatoma, hepatocarcinoma · ICD-10: C22.0
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, often developing in people with chronic liver disease. Clinical trial research is focused on developing new therapies, improving diagnostic methods, and preventing recurrence. Find a Trial helps patients search for active studies for HCC.
Search hepatocellular carcinoma trials →
Common questions about hepatocellular carcinoma clinical trials
What is hepatocellular carcinoma?
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, originating in the main liver cells (hepatocytes). It often occurs in individuals with underlying chronic liver conditions, such as cirrhosis. Research aims to understand its development and improve treatment options.
What types of clinical trials are available for hepatocellular carcinoma?
Clinical trials for HCC explore various approaches, including new drug therapies, immunotherapies, targeted treatments, and locoregional therapies. Some studies also focus on improving diagnostic tools or patient quality of life. Data from ClinicalTrials.gov shows a wide range of ongoing research.
Who is eligible to participate in HCC clinical trials?
Eligibility criteria vary by study but often include factors like the stage of cancer, liver function, overall health, and prior treatments. Patients should discuss their specific medical history with their healthcare team to determine if they meet a trial's requirements.
What are common research directions in HCC clinical trials?
Current research, as seen on NIH RePORTER and ClinicalTrials.gov, explores novel targeted therapies, immunotherapies, and combination treatments to improve patient outcomes. Studies also investigate biomarkers for early detection, prognosis, and personalized medicine approaches.
What are common interventions being studied for HCC?
Interventions include systemic therapies (like targeted drugs and immunotherapies), locoregional therapies (such as transarterial chemoembolization or radioembolization), and surgical techniques. Researchers are also evaluating new radiation therapies and combination approaches.
Are there specific biomarkers important in HCC clinical trials?
Yes, biomarkers like alpha-fetoprotein (AFP) are often used in HCC trials for diagnosis, prognosis, and monitoring treatment response. Researchers are also investigating new genetic and molecular biomarkers to predict drug effectiveness and identify novel therapeutic targets.
What are common reasons someone might be excluded from an HCC clinical trial?
Exclusion criteria often include uncontrolled co-existing medical conditions, severe liver dysfunction, active infections, or prior treatments that might interfere with the study drug. Each trial has specific requirements to ensure patient safety and data integrity.
Do patients have to pay to participate in HCC clinical trials?
Generally, study-related medical care and investigational drugs are provided at no cost to participants. However, standard medical care costs, travel, and lodging may not be covered. Patients should clarify financial details with the study team before enrolling.
How to find a hepatocellular carcinoma trial that fits you
- Describe your hepatocellular carcinoma situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all hepatocellular carcinoma trials →